Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The RNA-induced silencing complex (RISC) / Argonaute-2 (Ago2) machinery is a multi-protein ribonucleoprotein complex that serves as the core effector of the RNA interference (RNAi) pathway. At its catalytic center is Argonaute-2 (Ago2), an endonuclease (slicer) that binds small regulatory RNAs, such as microRNAs (miRNAs) and small interfering RNAs (siRNAs), to guide post-transcriptional gene silencing. Upon loading of a double-stranded RNA duplex, the passenger strand is discarded, and the remaining guide strand directs the complex to complementary target messenger RNAs (mRNAs). Perfect complementarity triggers Ago2-mediated endonucleolytic cleavage of the target mRNA, whereas partial complementarity leads to translational repression and mRNA decay. This machinery is highly exploited by therapeutic siRNAs to selectively silence disease-causing genes. Approved siRNA drugs, such as patisiran, inclisiran, and fitusiran, utilize this endogenous pathway to treat a variety of conditions, including amyloidosis, hypercholesterolemia, and hemophilia. However, therapeutic challenges include avoiding off-target effects from partial sequence matches and preventing the saturation of the endogenous RISC machinery, which could disrupt essential physiological miRNA pathways.
The RISC/Ago2 machinery is utilized by small interfering RNAs (siRNAs) to achieve sequence-specific gene silencing. Upon cellular uptake, the double-stranded siRNA is loaded into the RISC/Ago2 complex. The passenger strand is cleaved and discarded, while the guide strand is retained by Argonaute-2 (Ago2). The guide strand then directs the active RISC to complementary target mRNA transcripts via Watson-Crick base pairing, where the endonuclease (slicer) activity of Ago2 cleaves the target mRNA, leading to its degradation and subsequent inhibition of translation.
12 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA-induced silencing complex (RISC) / Argonaute-2 (Ago2) machinery (RISC/Ago2).